GLOBAL COST EFFECTIVE ANALYSIS OF APIXABAN VERSUS WARFARIN FOR THE PREVENTION OF STROKE AS A RESULT OF ATRIAL FIBRILLATION: A SYSTEMATIC REVIEW

被引：0
|
作者：
Petrenchik, L. [1 ]
Hussain, N. [1 ]
Charles, P. [1 ]
Peprah, H. [1 ]
Loh, F. E. [1 ]
机构：
[1] Touro Coll Pharm, New York, NY USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.372
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV50
引用
收藏
页码：S61 / S61
页数：1
相关论文
共 50 条
  • [41] Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis
    Carla Rognoni
    Monia Marchetti
    Silvana Quaglini
    Nicola Lucio Liberato
    Journal of Thrombosis and Thrombolysis, 2015, 39 : 149 - 154
  • [42] Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis
    Rognoni, Carla
    Marchetti, Monia
    Quaglini, Silvana
    Liberato, Nicola Lucio
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2015, 39 (02) : 149 - 154
  • [43] Apixaban (Eliquis) for Stroke Prevention in Atrial Fibrillation
    Beck, Robert A.
    King, William M.
    AMERICAN FAMILY PHYSICIAN, 2014, 89 (08) : 672 - +
  • [44] Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation
    Healey, Jeff S.
    Lopes, Renato D.
    Granger, Christopher B.
    Alings, Marco
    Rivard, Lena
    McIntyre, William F.
    Atar, Dan
    Birnie, David H.
    Boriani, Giuseppe
    Camm, A. John
    Conen, David
    Erath, Julia W.
    Gold, Michael R.
    Hohnloser, Stefan H.
    Ip, John
    Kautzner, Josef
    Kutyifa, Valentina
    Linde, Cecilia
    Mabo, Philippe
    Mairesse, Georges
    Benezet Mazuecos, Juan
    Cosedis Nielsen, Jens
    Philippon, Francois
    Proietti, Marco
    Sticherling, Christian
    Wong, Jorge A.
    Wright, David J.
    Zarraga, Ignatius G.
    Coutts, Shelagh B.
    Kaplan, Andrew
    Pombo, Marta
    Ayala-Paredes, Felix
    Xu, Lizhen
    Simek, Kim
    Nevills, Sandra
    Mian, Rajibul
    Connolly, Stuart J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (02): : 107 - 117
  • [45] Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease
    Altawalbeh, Shoroq M.
    Alshogran, Osama Y.
    Smith, Kenneth J.
    VALUE IN HEALTH, 2018, 21 (12) : 1365 - 1372
  • [46] COST CONSEQUENCE ANALYSIS OF APIXABAN VERSUS WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION IN THE MEXICAN PUBLIC HEALTH SECTOR
    Juarez-Garcia, A.
    Donato, B. M. K.
    Mucino-Ortega, E.
    Davila, A.
    Guirant-Corpi, L.
    VALUE IN HEALTH, 2014, 17 (03) : A109 - A109
  • [47] Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation
    Lip, Gregory Y. H.
    Kongnakorn, Thitima
    Phatak, Hemant
    Kuznik, Andreas
    Lanitiss, Tereza
    Liu, Larry Z.
    Iloeje, Uchenna
    Hernandez, Luis
    Dorian, Paul
    CLINICAL THERAPEUTICS, 2014, 36 (02) : 192 - 210
  • [48] Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial
    Garcia, David A.
    Wallentin, Lars
    Lopes, Renato D.
    Thomas, Laine
    Alexander, John H.
    Hylek, Elaine M.
    Ansell, Jack
    Hanna, Michael
    Lanas, Fernando
    Flaker, Greg
    Commerford, Patrick
    Xavier, Denis
    Vinereanu, Dragos
    Yang, Hongqiu
    Granger, Christopher B.
    AMERICAN HEART JOURNAL, 2013, 166 (03) : 549 - 558
  • [49] Stroke Prevention in Atrial Fibrillation A Systematic Review
    Lip, Gregory Y. H.
    Lane, Deirdre A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (19): : 1950 - 1962
  • [50] A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE
    Hess, Connie N.
    Al-Khatib, Sana M.
    Granger, Christopher B.
    Lopes, Renato
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2013, 11 (09) : 1105 - 1114
12345